Advertisement

Topics

Daiichi Pure Chemicals Company Limited Company Profile

09:29 EST 11th December 2018 | BioPortfolio

Drug Discovery

Location

3-13-5 Nihombashi Chuo-ku
Tokyo
Tokyo
103
Japan

Contact

Fax: 81 3 3272 0671


News Articles [792 Associated News Articles listed on BioPortfolio]

#Cannabisstocks: Pure Global Cannabis (TSX.V: PURE; OTC: PRCNF) Provides Update on Growing International Platform

TORONTO - August 23, 2018 (Investorideas.com Newswire) Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (the "Company" or "Pure Global" or "PURE"), a vertically-integrated, growth-oriented life sci...

Kitasato Daiichi Sankyo Vaccine to merge with Daiichi Sankyo

Daiichi Sankyo Company, Limited announced the scheme for the reorganization of Kitasato Daiichi Sankyo Vaccine Co, Ltd, a subsidiary of Daiichi Sankyo, into a subsidiary specializing in manufacturing ...

Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test

TOKYO and MUNICH and BASKING RIDGE, New Jersey, Nov. 27, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into an agreement with...

Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...

TOKYO and MUNICH and BASKING RIDGE, N.J., Oct. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety Read more...

Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (November 21, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accep...

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr...

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significan...

PubMed Articles [620 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

Diffuse axonal injury (DAI) in moderate to severe head injured patients: Pure DAI vs. non-pure DAI.

Diffuse axonal injury (DAI) is known to be associated with poor outcome. DAI often associates with other intracranial injuries but their distinct features have not been established. In this retrospect...

DEVELOPMENT OF A CURATED HERSHBERGER DATABASE.

A systematic literature review was conducted to identify Hershberger bioassays for ~3200 chemicals including those used to validate the OECD/US EPA guideline assay, US EPA's chemicals screened for end...

A Man (or a Woman) is Known by the Company He/She Keeps.

Headspace passive dosing of volatile hydrophobic chemicals - Aquatic toxicity testing exactly at the saturation level.

It is challenging to conduct aquatic tests with highly hydrophobic and volatile chemicals while avoiding substantial sorptive and evaporative losses. A simple and versatile headspace passive dosing (H...

Clinical Trials [485 Associated Clinical Trials listed on BioPortfolio]

Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa

The purpose of this study is to determine occurrence of pure red cell aplasia in a group of participants with chronic renal insufficiency and with resistance criteria to epoetin alfa treat...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System

The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Companies [2242 Associated Companies listed on BioPortfolio]

Daiichi Pure Chemicals Company Limited

Drug Discovery

Wako Chemicals USA, Inc

Wako Chemicals USA, Inc. is a wholly owned subsidiary of Wako Pure Chemical Industries, Ltd. of Japan. Wako Pure Chemicals Industries, Ltd., worldly renowned for its high purity chemicals, established...

Pure Via

Pure Via® is an all-natural, zero-calorie sweetener this is made from Rebaudioside A (Reb A), the sweetest, best-tasting part of the stevia leaf. Reb A is generally recognized ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

More Information about "Daiichi Pure Chemicals Company Limited" on BioPortfolio

We have published hundreds of Daiichi Pure Chemicals Company Limited news stories on BioPortfolio along with dozens of Daiichi Pure Chemicals Company Limited Clinical Trials and PubMed Articles about Daiichi Pure Chemicals Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Daiichi Pure Chemicals Company Limited Companies in our database. You can also find out about relevant Daiichi Pure Chemicals Company Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record